Strong increase in sales in 2021 and improved earnings outlook

Business overall saw a very dynamic development – especially in the last few months of 2021. On the one hand, extraordinary additional sales rose again in connection with COVID-19, while on the other hand, drug sales for cold and flu infections rose sharply year on year.

• Extraordinary additional sales in connection with COVID-19 had a positive sales effect of 3.1%.
• 50% growth of online sales at Amavita and Sun Store.
• The specialty pharmacy Mediservice achieved a high increase in sales of new rare disease medications in combination with home-care services.
• Acquisitions of companies and new products strengthened Galenica’s position in the Swiss healthcare market and opened up new market segments.
• Further market share gains in the wholesale business with doctors have made a positive contribution to sales growth.

Thanks to the exceptionally strong sales growth in the last few months of 2021 and the one-off gain from the property sale of the headquarters in Bern of about CHF 9 million Galenica is increasing its earnings outlook and now expects adjusted EBIT (excluding the effects of IFRS 16 and IAS 19) to grow by between +24% and +28%. In this context, Galenica expects an extraordinary EBIT contribution related to COVID-19 between +14% and +16%.

The Board of Directors will propose Judith Meier for election as a new member at the 2022 Annual General Meeting. Judith Meier has many years of experience in the operational and strategic management of service providers in the healthcare sector. With her proven expertise and valuable experience in strategically important areas of the Group’s activities, Judith Meier is the ideal addition to the Board of Directors of the Galenica Group, particularly with regard to key topics of the strategic Care programme.